HomeCompareSYRVF vs PFE

SYRVF vs PFE: Dividend Comparison 2026

SYRVF yields 3.30% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $26.3K in total portfolio value· pulled ahead in Year 9
10 years
SYRVF
SYRVF
● Live price
3.30%
Share price
$3.00
Annual div
$0.10
5Y div CAGR
-6.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.2K
Annual income
$192.80
Full SYRVF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SYRVF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYRVFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYRVF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYRVF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYRVF
Annual income on $10K today (after 15% tax)
$280.10/yr
After 10yr DRIP, annual income (after tax)
$163.88/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,156.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYRVF + PFE for your $10,000?

SYRVF: 50%PFE: 50%
100% PFE50/50100% SYRVF
Portfolio after 10yr
$36.4K
Annual income
$13,225.76/yr
Blended yield
36.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SYRVF
No analyst data
Altman Z
0.6
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYRVF buys
0
PFE buys
0
No recent congressional trades found for SYRVF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYRVFPFE
Forward yield3.30%6.13%
Annual dividend / share$0.10$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-6.7%13.2%
Portfolio after 10y$23.2K$49.6K
Annual income after 10y$192.80$26,258.71
Total dividends collected$2.5K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SYRVF vs PFE ($10,000, DRIP)

YearSYRVF PortfolioSYRVF Income/yrPFE PortfolioPFE Income/yrGap
1$11,007$307.45$9,153$693.39+$1.9KSYRVF
2$12,073$295.10$8,593$849.25+$3.5KSYRVF
3$13,200$282.22$8,336$1,066.78+$4.9KSYRVF
4$14,394$269.07$8,437$1,384.80+$6.0KSYRVF
5$15,657$255.82$9,013$1,875.40+$6.6KSYRVF
6$16,995$242.65$10,306$2,680.72+$6.7KSYRVF
7$18,415$229.67$12,820$4,101.38+$5.6KSYRVF
8$19,921$216.99$17,673$6,826.70+$2.2KSYRVF
9← crossover$21,520$204.68$27,543$12,591.86$6.0KPFE
10$23,219$192.80$49,560$26,258.71$26.3KPFE

SYRVF vs PFE: Complete Analysis 2026

SYRVFStock

Sacyr, S.A. engages in the construction and infrastructure concession services businesses worldwide. The company operates through Concessions, Engineering and Infrastructure, and Services divisions. It offers various construction services comprising civil engineering and buildings, as well as engineering and construction, and maintenance of industrial and oil and gas facilities. The company also engages in motorway, transport hub, airport, and hospital concessions business. In addition, it develops conventional and renewable energy facilities, photovoltaic and geothermal plants, and biomass energy systems; maintains power plants and industrial facilities; and designs, constructs, and operates waste treatment and waste-to-power plants, as well as manages processing plants and equipment. Further, the company engages in the implementation of refinery, chemical and petrochemical, gas handling and treatment, and liquefied natural gas projects; transportation and storage of fuels; and engineering development and construction of high-voltage electricity lines and electricity substations, as well as maintenance of medium and high-voltage electricity lines. Additionally, it offers environmental work and regeneration services; integrated water cycle management, water purification, desalination, and recycling services; facility management and maintenance, building cleaning, and ancillary services; and mining services, as well as involved in street cleaning; waste collection; sludge treatment; gardening and maintenance of green areas; parking meter management; towing; bicycle rental; and removal of vehicles from public thoroughfares. Sacyr, S.A. also engages in real estate development activities; the provision of catering services; and the operation of restaurants and hotels, petrol stations, and retail outlets. The company was formerly known as Sacyr Vallehermoso S.A. and changed its name to Sacyr, S.A. in August 2013. Sacyr, S.A. is headquartered in Madrid, Spain.

Full SYRVF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SYRVF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYRVF vs SCHDSYRVF vs JEPISYRVF vs OSYRVF vs KOSYRVF vs MAINSYRVF vs JNJSYRVF vs MRKSYRVF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.